

No increase in febrile seizures with 2010-2011 TIV or PCV13

15 September 2015



"No statistically significant increased risk of FS was found for 2010-2011 TIV or PCV13, when adjusting for concomitant vaccines," the authors write. "Same-day TIV and PCV13 vaccination was not associated with more FS compared with separate-day vaccination."

Two authors disclosed financial ties to health insurance companies.

More information: [Abstract](#)
[Full Text \(subscription or payment may be required\)](#)

(HealthDay)—For the 2010-2011 influenza season, there was no increase in the risk of febrile seizures (FS) with the trivalent inactivated influenza vaccine (TIV) or the 13-valent pneumococcal conjugate vaccine (PCV13), according to research published online Sept. 14 in *Pediatrics*.

Copyright © 2015 [HealthDay](#). All rights reserved.

Alison Tse Kawai, Sc.D, of Harvard Medical School in Boston, and colleagues examined the FS rate after TIV and PCV13 for a risk interval of zero to one days versus a control interval of 14 to 20 days as part of the Post-Licensure Rapid Immunization Safety Monitoring Program.

The researchers found no statistically significant TIV-FS associations in unadjusted or adjusted models. After adjusting for age and seasonality, PCV13 was significantly associated with FS (incidence rate ratio [IRR], 1.74; 95 percent confidence interval [CI], 1.06 to 2.86); but after further adjusting for concomitant TIV and diphtheria tetanus acellular pertussis-containing vaccines (DTaP), the association was not significant (IRR, 1.61; 95 percent CI, 0.91 to 2.82). Same-day vaccination with TIV and PCV13 was not associated with increased risk of FS compared with separate-day vaccination (1.08 fewer FS per 100,000 with same-day administration; 95 percent CI, ?5.68 to 6.09).

APA citation: No increase in febrile seizures with 2010-2011 TIV or PCV13 (2015, September 15)
retrieved 25 May 2022 from <https://medicalxpress.com/news/2015-09-febrile-seizures-tiv-pcv13.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.